BPX-501
Phase 2Cell therapy
BPX-501 is one of 46 biologic programs targeting Recurrent Disease. It is currently in Phase 2.
3
Indications
7
Total Trials
4
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Malignancies
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Cellcept
RochePhase 2
Eloxatin
TevaPhase 2
Prograf
VVeloxis Pharmaceuticals
Phase 2
Fluoropyrimidine
RochePhase 2
Gemzar
Johnson & JohnsonPhase 1
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 1
Tibsovo
SServier
Phase 1
Tuoyi
CCoherus Oncology, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stem Cell Transplant4 trials
Malignancies1 trial
Advanced Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPX-501. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- BBellicum Pharmaceuticals